BioNTech Results Presentation Deck
Updated Outlook for the 2021 Financial Year
Update on COVID-19 Vaccine Planned Deliveries for the 2021 Financial Year
Estimated BioN Tech COMIRNATY/COVID-19 vaccine revenues for the full 2021 financial year based on
up to 2.5 billion doses: €16 billion to €17 billion*
●
Planned 2021 Financial Year Expenses and Capex*
Previous cost guidance maintained for the full 2021 financial year
R&D expenses
SG&A expenses
Capital expenditure
34
€950 million - €1,050 million
€250 million - €300 million
€175 million - €225 million
Further ramp-up of R&D investment in Q4 2021 planned to expand and accelerate the pipeline development
Ranges reflect current base case projections
Estimated 2021 Financial Year Tax Assumptions
BioNTech Group estimated
annual effective income tax rate
*Figures have been estimated at constant foreign exchange rates.
-31%
BIONTECHView entire presentation